{
    "clinical_study": {
        "@rank": "99095", 
        "acronym": "2012-005003-40", 
        "arm_group": [
            {
                "arm_group_label": "Wobenzym\u00ae plus", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo equates Wobenzym\u00ae plus but without active ingredients", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the current study is to investigate the therapeutic effect and especially the\n      mode of action of Wobenzym\u00ae plus, an anti-inflammatory drug containing proteolytic enzymes,\n      on exercise induced muscle damage (eiMD) and recovery time in male amateur sportsmen with\n      medium proficiency level compared to placebo."
        }, 
        "brief_title": "Effects of Wobenzym\u00ae Plus in Healthy, Sportive People After Eccentric Exercise", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Muscle Injury", 
            "Muscle Soreness", 
            "Exercise Induced Muscle Damage"
        ], 
        "condition_browse": {
            "mesh_term": "Wounds and Injuries"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is able and willing to sign the Informed Consent Form prior to screening\n             evaluations\n\n          -  Subject is in good physical and mental health as established by medical history,\n             physical examination, electrocardiogram, vital signs, results of biochemistry,\n             haematology\n\n          -  Not anticipating any planned changes in lifestyle regarding activity and nutrition\n             for the duration of the study\n\n          -  Non smoker\n\n          -  Men with strength training experience\n\n          -  Age: 20-50 years\n\n          -  BMI \u226520 kg/m2 and \u2264 32 kg/m2\n\n          -  medium concentric strength ability (150-300 Nm)\n\n        Exclusion Criteria:\n\n          -  Relevant history or presence of any medical disorder, potentially interfering with\n             this trial (e.g. volunteers having experienced any cardiovascular events such as\n             infarction, angina, surgical endocoronary intervention, stroke or volunteers\n             suffering from diabetes as well as acute or chronic injury of the musculoskeletal\n             system, e.g. cruciate ligament rupture.\n\n          -  No intake of anti-inflammatory medication/ food supplements or intake of medications\n             that directly affect parameters of muscle function or performance within 4 weeks\n             prior to visit 1 or during the trial\n\n          -  Subjects not willing to abstain from intake of analgesic medication 24 hours prior to\n             and during visit 1 and 2.\n\n          -  For this trial clinically relevant abnormal laboratory, vital signs or physical\n             findings at screening\n\n          -  Known hypersensitivity to the study preparation or to single ingredients (e.g.\n             Lactose intolerance)\n\n          -  Drug, alcohol and/or medication abuse\n\n          -  Known HIV-infection\n\n          -  Known acute or chronic hepatitis B and C infection\n\n          -  Participation in another clinical trial within the last 4 weeks and concurrent\n             participation in another clinical trial\n\n          -  Blood donation within 4 weeks prior to trial start (visit 1) or during trial."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845558", 
            "org_study_id": "BTS651/12", 
            "secondary_id": "2012-005003-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "Wobenzym\u00ae plus", 
                "intervention_name": "Wobenzym\u00ae plus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo equates Wobenzym\u00ae plus but without active ingredients", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Wobenzym"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Muscle soreness", 
            "Exercise induced muscle damage", 
            "Inflammation", 
            "Proteolytic enzymes", 
            "Muscle strength Dynamometer"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "h.pabst@pwc-gmbh.de", 
                "last_name": "Helmut Pabst, Dr.", 
                "phone": "00490810573406310"
            }, 
            "facility": {
                "address": {
                    "city": "F\u00fcrstenfeld Bruck", 
                    "country": "Germany", 
                    "zip": "82256"
                }, 
                "name": "Sportschule FFb Puch GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Wobenzym\u00ae Plus in Healthy, Sportive People After Eccentric Exercise - a Randomized, Two-stage, Double-blind, Placebo-controlled Cross-over Trial", 
        "overall_contact": {
            "email": "h.pabst@pwc-gmbh.de", 
            "last_name": "Helmut Pabst, Dr. med", 
            "phone": "0049 810573406301"
        }, 
        "overall_official": {
            "affiliation": "PWC GmbH", 
            "last_name": "Helmut Pabst, Dr. med", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Multidimensional approach for recovery and acute phase after eccentric stress test. Will be assessed at different time points before and after an excentric stress test and the reduction of these parameters under treatment will be calculated.", 
            "measure": "Reduction of maximal concentric strength, movement induced pain and  pressure induced pain combined in a multidimensional (composite outcome)model giving information about the change induced by the stress test", 
            "safety_issue": "No", 
            "time_frame": "immediately before, 24h post, 48h post"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reduction of strength induced by the excentric stress test", 
                "measure": "Maximal concentric strength (Nm) before and after the stress test", 
                "safety_issue": "No", 
                "time_frame": "immediately before, 0h, 3h, 6h, 24h, 48h, 72h"
            }, 
            {
                "description": "Pain induced by the stress test rated via Algometry kg/cm*cm induced by standardised pressure", 
                "measure": "Pressure induced pain", 
                "safety_issue": "No", 
                "time_frame": "immediately before, 0h, 3h, 6h, 24h, 48h, 72h"
            }, 
            {
                "description": "Blood routine parameters (differentiated haemogram; blood lipids; glucose; kreatinin) as safety parameters", 
                "measure": "Blood routine parameters", 
                "safety_issue": "Yes", 
                "time_frame": "immediately before, 0h, 3h, 6h, 24h, 48h, 72h"
            }, 
            {
                "description": "Blood pressure and heart rate as safety parameter", 
                "measure": "blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "immediately before, 24h, 48h, 72h"
            }, 
            {
                "description": "Pain induced by a standardised movement and rated by the volunteer via VAS.", 
                "measure": "Movement induced pain", 
                "safety_issue": "No", 
                "time_frame": "immediately before, 0h, 3h, 6h, 24h, 48h, 72h post"
            }
        ], 
        "source": "Mucos Pharma GmbH & Co. KG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mucos Pharma GmbH & Co. KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}